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According to the 14th (2010) annual tuberculosis report bythe World Health Organization (WHO), there were an
estimated 9.4 million new cases of tuberculosis (TB) world-
wide.1,2 Increase in the incidence of new TB cases is seen mostly
within developing countries of Africa, Asia, and Latin America.
The emergence of MDR-TB (Multidrug Resistant TB) and
XDR-TB (Extensive Drug Resistant TB) strains are worrisome
as these are virtually untreatable with the existing panel of anti-
TB drugs. It is estimated, in 2009, that 3.3% of all new TB cases
are MDR-TB positive and XDR-TB positive cases are distributed
in 58 countries. It is important to ﬁnd new aﬀordable and
eﬀective antituberculosis drugs to reduce the physical and
economic burden of TB patients. The mycobacterial cell wall is
regarded as a validated target for developing new anti-TB drugs,
as ﬁrst-line anti-TB drugs including ethambutol and isoniazid
inhibit synthesis of arabinan and mycolic acids, key constituents
of the cell wall of Mycobacterium tuberculosis. The cell wall
provides a permeability barrier, shielding the bacterium from
degradative forces as well as modulating host immune responses
to its own needs and presenting special problems for disease
chemotherapy. The cell envelope possesses two major structural
components: the plasma membrane and the wall proper. The
plasma membrane is characterized by the presence of the
phosphatidylinositol mannosides lipomannan and lipoarabino-
mannan (LAM) but, in other respects, appears typical of bacterial
membranes. The cell wall however, is highly distinctive and
characterized by a “core” consisting of covalently linked mycolic
acids, the unusual heteropolysaccharide-arabinogalactan, and
peptidoglycan (mAGP complex). mAGP is composed of three
arabinan chains attached to the homogalactan core. The homo-
arabinan chains are composed of linear R-D-Araf residues with
branching produced by 3,5-linked R-D-Araf residues substituted
at both positions by R-D-Araf residues. On the other hand, the
R-(1f5)-linked arabinan chains of LAM terminate in either one
of the two well-deﬁned motifs, namely, a branched Ara6 or a
linear Ara4, the relative proportion of which reﬂects the amount
of R-(1f3)-linkage branching of the R-(1f5)-linked arabinan
backbone, prior to termination by β-(1f2)-arabinosylation. It
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ABSTRACT: Arabinosyltransferases are a family of membrane-
bound glycosyltransferases involved in the biosynthesis of the
arabinan segment of two key glycoconjugates, arabinogalactan and
lipoarabinomannan, in the mycobacterial cell wall. All arabinosyl-
transferases identiﬁed have been found to be essential for the growth
ofMycobcterium tuberculosis and are potential targets for developing
new antituberculosis drugs. Technical bottlenecks in designing
enzyme assays for screening for inhibitors of these enzymes are (1) the enzymes are membrane proteins and refractory to
isolation; and (2) the sole arabinose donor, decaprenylphosphoryl-D-arabinofuranose is sparingly produced and diﬃcult to isolate,
and commercial substrates are not available. In this study, we have synthesized several analogues of decaprenylphosphoryl-D-
arabinofuranose by varying the chain length and investigated their arabinofuranose (Araf) donating capacity. In parallel, an essential
arabinosyltransferase (AftC), an enzyme that introduces R-(1f3) branch points in the internal arabinan domain in both
arabinogalactan and lipoarabinomannan synthesis, has been expressed, solubilized, and puriﬁed for the ﬁrst time. More importantly,
it has been shown that the AftC is active only when reconstituted in a proteoliposome using mycobacterial phospholipids and has a
preference for diacylated phosphatidylinositoldimannoside (Ac2PIM2), a major cell wall associated glycolipid. R-(1f3) branched
arabinans were generated when AftCliposome complex was used in assays with the (Z,Z)-farnesylphosphoryl D-arabinose and
linear R-D-Araf-(1f5)35 oligosaccharide acceptors and not with the acceptor that had a R-(1f3) branch point preintroduced.
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has been shown that all Araf residues in mycobacterial D-arabinan
originate from the pentose phosphate pathway/hexose mono-
phosphate shunt, and the immediate precursor is decaprenylpho-
spho-D-arabinofuranose (DPA). The biosynthetic pathway for
the DPA formation has been recently elucidated.3,4 Recently, an
enzyme, decaprenylphosphoryl-β-D-ribose-20-epimerase (DprE),
involved in the synthesis of decaprenylphosphoryl-D-arabinofur-
anose (DPA), the arabinose donor for arabinan synthesis, has
been identiﬁed as the target for benzothiazinone and dinitro-
benzamide derivatives, new classes of antituberculosis candi-
dates.5,6 These compounds are now in a phase 2 clinical trials.7
Although the structural scaﬀold and the biosynthetic steps in
mycobacterial arabinan formation have been almost completely
elucidated,812 screening for inhibitors against arabinosyltrans-
ferase (AraT) activity has not been pursued because of diﬃculties
associated with obtaining soluble, active proteins for biochemical
assays. This is largely due to the fact that all knownmycobacterial
AraTs are membrane proteins with multiple membrane spanning
domains. As shown in Figure 1, AraTs dedicated to the arabino-
galactan (AG) synthesis pathway include AftA (Rv3792), appar-
ently responsible for the transfer of the ﬁrst Araf residue to the
galactan domain of AG,13 the terminal β-(1f2)-capping AftB
(Rv3805c),14 AftC (Rv2673) involved in the synthesis of the
internal R-(1f3)-branching of the arabinan domain of AG,15
and the EmbA and EmbB proteins involved in the formation
of the [β-D-Araf-(1f2)-R-D-Araf]2-3,5-R-D-Araf-(1f5)-R-
D-Araf- (Ara6) termini of arabinan.
12 On the contrary, interest-
ingly, only three enzymes, EmbC, AftC, and AftD (Rv0236c),
have been implicated in lipoarabinomannan (LAM) arabinan
synthesis.16,17,20 The donor substrate (DPA) used in the AraT
enzymatic assays is produced by Mycobacterium sp. at very low
level and is not commercially available. Preparation of DPA from
mycobacteria is laborious and time-consuming and is often
obtained in poor yield18 and therefore not suitable for develop-
ment of high throughput assays. Moreover, due to the long chain
length in the lipid, DPA has poor solubility in aqueous buﬀers.
As an alternate, phosphoribose pyrophosphate (pRpp) has been
utilized in many assays.1921 This highly soluble precursor can
be transformed to DPA in situ in an enzymatic reaction.3 How-
ever, because of the ﬁve steps involved in the conversion of
pRpp to DPA, overall product formation is often ineﬃcient
(approximately 4% overall yield).21
In this study, we were able to express (after inducing with
acetamide)AftC inMycobacerium smegmatis (M. smegmatis), purify
the recombinant protein, and reconstitute it in a proteoliposome
retaining the AraT activity in enzymatic assays. In addition,
we synthesized several DPA analogues carrying shorter lipid
chains (C10, C15, and C35). These compounds (Figure 2A), (ω,
Z)-nerylphosphoryl D-arabinose (Z-NPA), (ω,Z,Z)-farnesylpho-
sphoryl D-arabinose (Z-FPA), (ω,E,E)-farnesylphosphoryl D-ara-
binose (E-FPA), and (ω,E,E,Z,Z,Z,Z)-heptaprenylphosphoryl D-
arabinose (Z-HPA), were assessed as artiﬁcial donors for AraT
assays with speciﬁc synthetic linear arabinofuranosyl acceptors.
’RESULTS AND DISCUSSION
Chemical Syntheses of DPA Analogues (Scheme 1). The
chemical syntheses of all DPA analogues used a common inter-
mediate, 2,3,5-(tri-tert-butyldimethylsilyl)-D-arabinosyl phosphate,
that was obtained by coupling dibenzyl phosphate with 2,3,5-(tri-
tert-butyldimethylsilyl)-D-arabinosyl bromide.22,23 The β-anomer
of the arabinoside was produced in 75% yield in the R/β mixture
(as estimated by 1H NMR). In the reaction step of coupling
arabinosyl bromide with dibenzyl phosphate, a rigorous drying of
bromide and dibenzyl phosphate intermediates in advance was
necessary to improve the proportion of β-anomer in the products
Figure 1. Structure and putative biosynthesis of arabinanmotif in AG inMycobacterium spp. There are three Ara22 (one is drawn in the ﬁgure) motifs on
the galactan backbone in AG. All Araf residues are donated by DPA. The AraTs (six in total) identiﬁed are shown. AftA (Rv3792) is a priming AraT and
donates the ﬁrst Araf on the galactan.13 AftB (Rv3805c) is a capping AraT and terminates the arabinan chain presumably after branching has been
introduced by EmbA/EmbB.12,14 Both AftC (Rv2673) and AftD (Rv0236c) have been shown to exhibit internal branching (R-(1f3)-AraT)
activity.15,20 All AraTs are essential in M. tuberculosis and have not been isolated for detailed functional studies. EmbA, EmbB, and AftD could be
bifunctional enzymes. AftC has been shown to be nonessential in M. smegmatis.
821 dx.doi.org/10.1021/cb200091m |ACS Chem. Biol. 2011, 6, 819–828
ACS Chemical Biology ARTICLES
of arabinosyl phosphate. Although the β-anomer could not be
completely separated from the R-anomer by column chromatog-
raphy, the early eluting fractions were enriched in the β-anomer
(∼88%). Alcohols containing the lipid chains (C10, C15, C35)
were activated by forming trichloroacetimidate intermediates.
Although the trichloroacetimidates were sensitive to moisture
and temperature, they could be stored at 20 C in a desiccator
for several days. Finally, the arabinosyl phosphate was coupled with
trichloroacetimidates in toluene. Deprotection of the coupled
products with ammonium fluoride in a 15% methanolic ammo-
niumhydroxide followed by chromatography on silica gel gave pure
DPA analogues. (Details in Supporting Information Scheme S1).
Chemical synthesis of DPA described initially used phosphor-
amidite-phosphite triester methodology, which yielded a β/R
ratio of 0.25.24 However, only the β-anomer of DPA has proven
to be a suitable donor for Araf. In our present work for the
synthesis of DPA analogues, an optimized approach was applied
to increase the proportion of the β-anomer in an anomeric
mixture (β/R ratio of 3) and with this anomeric mixture also
increased the yield of the product three-fold compared to using
the ones synthesized earlier.
Cell-Free Assay. We first wanted to determine whether the
DPA analogues would be effective in a cell-free assay using
membrane preparation (100,000  g pellet) from M. smegmatis
Figure 2. (A) Structure of DPA and DPA analogues used in this study. “Z”, “E”, and “ω” represent the conﬁguration of the double bonds in the lipids in
DPA and DPA analogues. Abbreviations: (ω,Z)-nerylphosphoryl D-arabinose (Z-NPA), (ω,Z,Z)-farnesylphosphoryl D-arabinose (Z-FPA), (ω,E,E)-
farnesylphosphoryl D-arabinose (E-FPA), (ω,E,E,Z,Z,Z)-heptaprenylphosphoryl D-arabinose (Z-HPA). (B) The structure of the acceptors 15 used in
the assays. Acceptor 1 is a branched pentasaccharide that was used for probing a R-(1f5) AraT activity, and acceptors 25 are linear oligosaccharides
from dimer to pentamer that were used for probing the R-(1f3) AraT (AftC) or β-(1f2) AraT (AftB).
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as the enzyme source. One specific pentasaccharide (acceptor 1,
structure shown in Figure 2B), octyl (R-D-Araf)2-(1f3,5)-R-D-
Araf-(1f5)-R-D-Araf-(1f5)-R-D-Araf, was used as an acceptor
(200 μM concentration) to assay for R-(1f5) AraT activity.21
This acceptor was selected because of its efficiency and specificity
in a cell-free assay in which a mixture of all AraT activities are
present. In order to examine the contribution of the length (C10,
C15, or C35) and configuration of the double bonds (Z or E) in
the lipid chains to the donor efficiency in the assay, we assessed
the ability of Z-NPA, Z-FPA, E-FPA, and Z-HPA in serving as
donor substrates. The enzymatic reaction mixture without
further processing was per-O-methylated and directly analyzed
by MALDI-TOF-MS. As shown in Figure 3, molecular ions
corresponding to unreacted acceptor (m/z 967) and an enzy-
matic product (m/z 1127) as sodium adducts were observed.
Additionally, several phosphatidylinositol mannoside (PIMs)
and other endogenous components present in the membranes
could also be detected (methylated PIM2 atm/z 877, methylated
PIM3 at m/z 1081, methylated PIM4 at m/z 1285, methylated
PIM5 at m/z 1489, methylated PIM6 at m/z 1693). By quanti-
fication of the relative intensity of the acceptor (m/z 967) and
the product (m/z 1127) reflected in the mass spectrum using
a standard curve (see Methods), the conversion rate (activity)
of DPA analogues could be estimated. The Z-FPA exhibited
the best Araf-donating activity (Figure 3B). However, the E-
FPA that possessed the same length of lipid as Z-FPA had no
Araf-donating activity (Figure 3C). The Z-NPA and Z-HPA
exhibited moderate conversions (Figure 3A and D).
AraT Competition Assay. To confirm the AraT activities of
DPA analogues, we evaluated the ability of unlabeled polyprenyl-
P-Araf (Z-NPA, Z-FPA, E-FPA, and E-HPA) to inhibit the
incorporation of labeled Araf from DP[14C]A generated in situ
from the p[14C]Rpp into the product. The results showed that
the addition of Z-FPA led to 54% inhibition of the DP[14C]A
(Figure 4B). In contrast, E-FPA only marginally affected the
DP[14C]A incorporation (11% inhibition), indicating a limited
competition of the lipids in the E-configuration. In addition, Z-
NPA and Z-HPA showed 10% and 35% inhibitory ability,
respectively. As is evident from the TLC (Figure 4A), formation
of DPA and DPR (decaprenylphosphoryl-D-ribofuranose) also
decreased dramatically using Z-FPA as competitor. It indicates
that one of the biosynthetic steps in the transformation of
p[14C]Rpp to DP[14C]A could also be inhibited by Z-FPA.
Thus, we have been successful in identifying the diﬀerential
inhibitory properties of the DPA analogues in the AraT assay
using DP[14C]A as donor. The enzyme has a preference for
Z-FPA compared to all other DPA analogues synthesized in this
work (Figure 4B).
Expression of AftC and Development of AraT Assays
Using AftC-Proteoliposome and DPA Analogues. A recom-
binant His6-tagged AftCwas efficiently produced inM. smegmatis
mc2155/pJAM/Rv2673 upon induction of the expression of
Scheme 1. Synthesis of DPA Analogues
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the aftC gene with acetamide.25 The His6-tagged recombinant
protein could be detected by Western blot (migrating at
∼38 kDa) in the transformants. Cells from AftC overexpressor
were disrupted by sonication and solubilized in 1% Igepal CA-
630, a detergent proven to retain AraT activity.14 The resulting
supernatant after centrifugation was nickel-affinity column pur-
ified by eluting with imidazole. Fractions (50200 mM imi-
dazole) containing His6-tagged AftC were monitored by SDS-
PAGE and Coomassie stain (Figure S1 in Supporting In-
formation), and ∼200 μg of partially purified protein was
obtained from 1 L of cell culture. The identity of the AftC was
confirmed using in-gel trypsin digestion and analysis of the
peptides by mass spectrometry, matching the masses with
MASCOT searching (score 122, Figure S2 in Supporting
Information).
Enzymatic assays were next designed to compare the ability of
M. smegmatis mc2155/pJAM and mc2155/pJAM/Rv2673 cell-
free extracts to transfer Araf from the DPA analogues onto
acceptor 2. No signiﬁcant increase in product formation was
observed (1.3-fold increase over the control). However, when
only the aﬃnity puriﬁed recombinant AftC protein was used in
the assay, we were unable to detect any product. On the other
hand, when recombinant AftC was combined withM. smegmatis
membranes from the overexpressing strain, product formation
increased 2.3-fold (results not shown).
We reasoned that the failure of the recombinant protein to
catalyze product formation was perhaps due to a lack of normal
environment of membrane or misfolding of the protein. It has
been reported that GT-C membrane proteins require lipids for
folding to retain structure and glycosyltransferase activity.26 On
the basis of this hypothesis, we developed a reconstitution system
forming a liposome using lipid extracts. At ﬁrst we used commer-
cially available dipalmitoyl phosphatidylcholine (DPPC) to re-
constitute, but the resulting liposome failed to generate active
enzyme. Then the puriﬁed AftC was reconstituted with native
lipid (CHCl3/CH3OH/H2O (10:10:3)) extracts from M. tuber-
culosis H37Rv cells to form AftC proteoliposome. Since both
Z-FPA (C15) and Z-HPA (C35) worked well in the AraT assay,
Figure 3. MALDI-TOF-MS spectra of enzymatic product by using Z-NPA (A), Z-FPA (B), E-FPA (C), and Z-HPA (D) in the cell-free assay using
membranes fromM. smegmatis; m/z 967 represents the methylated acceptor 1 and m/z 1127 represents the methylated product. Several endogenous
components, such as PIMs, can be observed in the mass spectra as the product is not puriﬁed from the reaction mixture.
Figure 4. Competitive assay. (A) TLC proﬁle of the reactions (using
pR[14C]-pp) in competition against the DPA analogues including Z-
NPA (lanes 3a and 3b), Z-FPA (lane 4a and 4b), E-FPA (lane 5a and
5b), andZ-HPA (lane 6a and 6b). Lanes 2a and 2b represent the reaction
without any competitor (negative control). Lane 1 exhibits the reaction
without using acceptor 1 (positive control). The std lane represents the
enzymatic product puriﬁed by column chromatography; “a” and “b”
represent the duplicate of one competitive assay. The bands that
migrated above the enzymatic product contained the [14C]-DPA and
[14C]-DPR that were produced from p[14C]Rpp. (B) Comparison of
the scintillation intensity of the competitive assays using the DPA
analogues as the competitors. The relative intensity was evaluated
according to the assay without using the competitors, which was
normalized to 100%.
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we used these compounds as sugar donors in separate reactions
from which AftC would transfer Araf(s) to the acceptors.
In our earlier work, we had chemically synthesized arabinofur-
anosyl acceptors that represent various structural domains in the
arabinan of AG and LAM. In the cell-free assay where all AraT
activities are present, using p[14C]Rpp as a donor, we were able
to demonstrate that a disaccharide acceptor Ara2, octyl R-D-
Araf-(1f5)-R-D-Araf (acceptor 5), yielded the speciﬁc product
octyl β-(1f2)-Araf-(1f5)-R-D-Araf-(1f5)-R-D-Araf, and oc-
tyl (R-D-Araf)2-(1f3,5)-R-D-Araf-(1f5)-R-D-Araf-(1f5)-R-
D-Araf (acceptor 1) gave a hexa-arabinoside21 with a single Araf
residue added on to the acceptor. Thus the acceptor speciﬁcity
was evident even when a mixture of AraTs was present in an
assay. We then asked which arabinan structure would AftC
proteoliposome prefer for its activity.
Five diﬀerent arabinofuranosyl acceptors (1 mM concen-
tration) were tested in the enzymatic reactions using the AftC
proteoliposome and DPA analogues. One of the acceptors was a
branched pentasaccharide (acceptor 1), and the others were
linear oligosaccharides (acceptors 25, structures shown in
Figure 2B) including Ara5, octyl R-D-Araf-(1f5)-R-D-Ara-
f-(1f5)-R-D-Araf-(1f5)-R-D-Araf-(1f5)-R-D-Araf (acceptor
2); Ara4, octyl R-D-Araf-(1f5)-R-D-Araf-(1f5)-R-D-Araf-(1f
5)-R-D-Araf (acceptor 3); Ara3, octyl R-D-Araf-(1f5)-R-D-Ara-
f-(1f5)-R-D-Araf (acceptor 4); and Ara2, octylR-D-Araf-(1f5)-
R-D-Araf (acceptor 5).
Direct mass spectral analyses of the reaction mixtures revealed
that the products formed in reactions with acceptors 24 only
and showed evidence of transfer of a single Araf onto each of the
acceptors tested. No products were detected for either acceptor 1
or 5. We concluded that AftC can only transfer Araf when a
minimum of three Araf residues are present in a linear structure
as in acceptors 24 in order to introduce an R-D-Araf-(1f3)
branch point15,17 (Figure S3 in Supporting Information). In fact,
in AG or LAM internal R-(1f3) branching is evident only after
three linear R-(1f5)-Araf residues have been assembled.27,28
Consequentially, the Ara2 (acceptor 5) could not form a tris-
accharide with AftC as it is recognized as a substrate by AftB to
form a β-(1f2)-Araf linkage14,29 (Figure 1). Furthermore, linear
Ara5 acceptor 2 could generate an enzymatic product with a mass
at 1127 [Mþ Na]þ and 1143 [Mþ K]þ as shown in Figure 5A
and B when using Z-FPA and Z-HPA as a donor, respectively;
acceptor 1with aR-(1f3)-Araf branch already introduced could
not yield any product with AftC proteoliposome (panel C,
Figure 5). This acceptor 1 has been proven to be speciﬁc for a
R-(1f5) arabinosyltransferase that has yet to be identiﬁed.21
AftC has recently been reported to display a R-(1f3)
branching AraT activity on a synthetic linear R-(1f5) linked
Ara5 acceptor in vitro.
15 One characteristic feature of AftC is that,
unlike other AraTs described, the gene is nonessential in M.
smegmatis and knockout mutants could be generated, an attri-
bute reminiscent of the Emb proteins.12,16 Phenotypic analysis of
the mutants in Corynebacterium glutamicum and M. smegmatis
showed that this enzyme is responsible for R-(1f3) branching
of the inner core of arabinan domain of AG (Figure 1) and LAM.
Although AftC belongs to the glycosyltransferase superfamily
C (GT-C) and is a membrane-associated protein with 1012
membrane spanning domains,10 we have been successful in
overexpressing and purifying a soluble form of AftC and have
shown that it retains activity in an in vitro assay after success-
ful reconstitution in proteoliposome using mycobacterial lipids.
In addition, we were able to show that use of DPA can be
substituted using some of the short chain synthetic DPA ana-
logues, preferably the analogue containing a moderate-length
lipid (C15). In mass spectrometric analysis and quantiﬁcation
of the enzymatic product formed (Supporting Information
Figure 5), Z-FPA exhibited the highest Araf-donating activity,
and 19.4% conversion was observed in a typical 2 h assay
(Figure 3B). However, the E-FPA that possessed the same length
of lipid as Z-FPA had no ions at m/z 1127 and hence was
considered to have zero percent conversion (Figure 3C). Z-NPA
(7.9% conversion) and Z-HPA (17.4% conversion) exhibited
low to moderate conversions (Figure 3A and D). Furthermore,
we have also shown that the DPA analogues containing lipids
with isoprenes in the Z-conﬁguration are competitive substrates
for DPA in the AraT assays. DPA has a unique stereoconﬁgura-
tion and contains all of the isoprene residues at theR-end in theZ
conﬁguration and only one trans (E)-isoprene residue at its ω-
end (Figure 2).30 This is in contrast with most bacteria that use
C55-undecaprenol phosphate, consisting of 11 isoprene units in
Figure 5. MALDI-TOF-MS in the positive ionization mode of the enzymatic products using the AftC proteoliposome and DPA analogues. The
substrates including the acceptors and donors (DPA analogues) used in the assay were (A) acceptor 2 and Z-FPA; (B) acceptor 2 and Z-HPA; (C)
acceptor 1 and Z-FPA. Them/z 1127 (þNa) andm/z 1143 (þK) represent the enzymatic product, andm/z 967 (þNa) andm/z 983 (þK) represent
the unconsumed acceptor.
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the ω-di-E/octa-Z conﬁguration. Our data suggests that for
optimal Araf donating capability, isoprene units in the ω-di-Z
conﬁguration as in Z-FPA are suﬃcient and it is not necessary to
introduce E-conﬁguration in the ω-end as in the Z-HPA. We
believe that lipids in the Z-conﬁguration are favored because
structurally Z-FPA is to some extent similar to DPA, which also
contains Z-isoprene units. Moreover, there is precedence in the
literature showing that membrane-associated enzymes involved
in undecaprenyl-dependent pathways often accept shorter (10
15 carbon) lipid substituents in vitro.31,32 The enhanced solubi-
lity of Z-FPA (C15) could be a second favorable factor for its
optimal Araf-donating activity. In our hands Z-NPA (ω-mono-Z
conﬁguration) could donate an Araf residue to the acceptor
although not eﬃciently. This was in contrast to the earlier
report33 that showed no activity. One reason for this discrepancy
is perhaps thepredominant presence of R-anomer in the earlier
preparation.
All AraTs described are membrane proteins of the GT-C
family. One characteristic feature of these proteins is that these
are membrane bound, which beat all odds for isolation and
puriﬁcation. Even if these are isolated with diﬃculty, after expres-
sion and puriﬁcation, GT-C membrane proteins are mostly
insoluble and aggregate easily.26 Therefore, developing an eﬃ-
cient assay to pursue functional studies on AftC or to screen for
inhibitors has been problematic. We have been able to express
and purify AftC and have shown that it has R-(1f3) AraT
activity when reconstituted in a proteoliposome. Repeated at-
tempts to express AftC and obtain it in large amounts in E. coli
pLySS, BL21, or C43 strains34 have failed, suggesting toxicity of
the protein in a nonmycobacterial host. Experiments with other
host strains of E. coli for expression of aftc are currently ongoing.
In vitro assay using the puriﬁed recombinant AftC and DPA
failed to give any product. However, with the successful recon-
stitution of AftC-proteoliposome and replacement of DPA with
analogues Z-FPA or Z-HPA, we were able to improve the in vitro
assay with product formation in reasonable amounts. For restor-
ing AraT activity for AftC, reconstructing a lipid environment
seemed to be a crucial factor. The inactivity of the proteolipo-
some using DPPC might because (1) DPPC does not mimic the
mycobacterial membrane well since it is positively charged and
bacterial membranes are negatively charged; (2) DPPC is not
present in mycobacterium and therefore it is not recognized by
AftC; (3) a combination of phospholipids from M. tuberculosis
are necessary for creating a “real” mycobacterial membrane
environment mimicking the cell membrane that will foster
proper folding of AraT. Mycobacterial lipid extracts are domi-
natedwith the presence of the phospholipids such as the family of
phosphatidylinositol mannosides (PIMs). We reasoned that
these lipids are required to mimic the membrane environment.
When we fractionated the lipid extract into individual bands
using preparative TLC, a lipid (Band IV) (Supporting Informa-
tion Figure S4A and Chart S4B) showed better activity than
other lipids for fabricating AftC proteoliposome (Supporting
Information, Figure S4C). Mass spectral analysis revealed Band
IV contained predominantly diacylPIM2 (Ac2PIM2) with con-
siderable heterogeneity in the fatty acyl composition (Ac2PIM2-
16:0/16:0/16:0/19:0; 16:0/16:0/18:0/19:0; 16:0/16:0/18:0/
18:0) (Supporting Information, Figure S6), indicating that these
phospholipids are important aspects in retaining AftC AraT
activity. Since these experiments were carried out in the absence
of membranes, this lipid-dependent activity could be a function
of intrinsic interactions between the donor lipid and the enzyme.
We further speculate that Ac2PIM2 supports an active conforma-
tion of the enzyme. More work needs to be done to understand
this result.
D-Araf is unique tomycobacteria and is a constituent of the two
most important macromolecules, AG and LAM, that play signi-
ﬁcant physiological and biological roles. The enzymes involved in
the polymerization of AG and LAM have been suggested to
present future opportunities for developing new therapeutics.30
The facts that Ethambutol, a ﬁrst line antituberculosis drug,
inhibits arabinan synthesis35 and new compounds have been
identiﬁed that are capable of inhibiting the formation of DPA,
also inhibiting M. tuberculosis grown intracellularly, support this
notion.5 Our present study describes isolation of one important
AraT whose functional studies can now be pursued as a result
of its availability in a recombinant form. AftC is essential in
M. tuberculosis,36 although a knockout mutant can be obtained in
M. smegmatis. Thus, it is important to develop assays for the
screening of small molecule inhibitors. The assay developed
bypasses use of radioactive pRpp, isolation of DPA, and use of
membrane preparations in which all AraTs are present.
Our ongoing eﬀorts encompass (1) expression of aftC to
produce larger quantities in E. coli to pursue functional aspects of
AftC, (2) replacement of the aglycon on the acceptors with
an “octylamine” tag for development of novel assays based
on carbohydrate microarrays for small molecule screening,
(3) demonstration that AftC is a valid anti-TB target, and
(4) reﬁnement of several assay parameters to increase the
conversion rate of the enzymatic reaction, including optimization
of detergents for protein dissolution and lipids for proteolipo-
some formation.
’METHODS
Syntheses of the DPA Analogues. The syntheses of DPA
analogues were performed according to established methods.37,38 The
detailed synthetic procedure and spectroscopic data are presented in the
Supporting Information.
Cell-Free Assays and Structural Analyses of the Enzymatic
Products. Typical assay reaction mixtures contained buffer A that has
50 mMMOPS (pH 7.9), 5 mM 2-mercaptoethanol and 10 mMMgCl2,
ATP (62.5 μM), DPA analogues (1 mM), acceptor 1 (200 μM), and
membranes (1.0 mg) in a total volume of 100 μL. The cell membranes
were prepared from M. smegmatis according to the established
procedure.21 The reaction mixtures were incubated at 37 C for 2 h
and terminated by adding 666 μL of 1:1 CHCl3/MeOH to make a final
solution of CHCl3/MeOH/H2O, 10:10:3. The reaction mixture was
centrifuged at 14,000 rpm for 10 min. The supernatant was then
evaporated to dryness. The dried reaction mixtures without further
processing were per-O-methylated, and resulting residues were dis-
solved in 50 μL of CHCl3. One microliter of sample was mixed with
1 μL of 2,5-dihydroxy benzoic acid (DHB, 10 mg mL1 in 50%
acetonitrile, 0.1% trifluoroacetic acid). The mixture was spotted on
theMALDI target and allowed to air-dry. The sample was analyzed by an
Ultraflex-TOF/TOF mass spectrometer (Bruker Daltonics, Billerica,
MA) in positive ion, reflector mode using a 25 kV accelerating voltage.
External calibration is done using a peptide calibration mixture (4 to
6 peptides) on a spot adjacent to the sample. The data was processed in
the FlexAnalysis software (version 2.4, Bruker Daltonics).
Competitive Assay. The competition assays were performed
according to the typical radioactive assay using DPA analogues as
competitors. In brief, reaction mixtures contained buffer A (as above,
pH 7.9) with 62.5 μM ATP, 0.8 μM p[14C]Rpp (100,000 dpm),
acceptor 1 (300 μM), 80 μM unlabeled competitors (Z-NPA, Z-FPA,
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E-FPA or E-HPA), membranes (0.5 mg) and cell wall extracts (P60,
0.3 mg)19 in a total volume of 160 μL. The reaction mixtures were
incubated at 37 C for 1 h and then terminated by adding 160 μL of
ethanol. The resulting mixture was centrifuged at 14,000  g, and the
supernatants were passed through prepacked strong anion exchange
(SAX) columns. The columns were eluted with 2 mL of water. The
eluent was evaporated to dryness and partitioned between the two
phases (1:1) of water saturated 1-butanol and water. Using liquid scin-
tillation counting, the 1-butanol fractions were measured for radio-
activity incorporation. For TLC analysis of the enzymatic products
formed in the competition assay, an aliquot of the 1-butanol fraction
was dried under air, and the residue was reconstituted in Milli-Q water
(10 μL) for analysis by silica gel TLC. The TLC plate was chromato-
graphed in CHCl3/MeOH/1 M NH4OAc/NH4OH/H2O (180:140:9:
9:23) followed by autoradiography at 70 C using Biomax MR film
(Kodak).
Overexpression of AftC (Rv2673) in M. smegmatis. The
entire coding sequence of Rv2673 was PCR amplified from M. tubercu-
losis H37Rv genomic DNA using the primers Rv2673pJAMS forward-
(50-cggagatctgtgtacggtgcgctggtgacgg-30) and Rv2673pJAMS reverse(50-
ccctctagaccgctggccctcccgctcgg-30), excised with BglII and XbaI, and
cloned into the compatible BamHI and XbaI restriction sites of the
expression vector pJAM2.25 The resulting plasmid, pJAMRv2673, allows
the inducible expression of Rv2673 under control of the acetamidase
promoter. The recombinant protein produced with this system had a
hexa-histidine at its carboxyl terminus allowing its purification using
metal affinity columns and detection by immunoblotting with the
monoclonal Penta-His antibody from QIAGEN. Synthesis of Rv2673
in mc2155/pJAMRv2673 cells grown at 37 C in MM63 broth was
induced during log phase with 0.2% acetamide for 12 h. The M.
smegmatis control strain carried the empty plasmid, pJAM2. Cells were
harvested by centrifugation (3,000 rpm) and frozen at 80 C until
further use.
Generation of His6-AftC. Frozen cells were thawed on ice and
suspended in 50 mM Tris-HCl buffer (pH 7.9) containing 150 mM
NaCl (pH 8.0), and protease inhibitor (EDTA-free, Roche), DNAase,
and Igepal CA-630 [1.0% (v/v)] were added to the cell suspension. Cells
were disrupted by probe sonication on ice (10 cycles at 60 s on and 90 s
off). Cell debris was removed by centrifugation (10,000  g, 15 min,
4 C). Soluble cell lysate was applied to affinity column containing
Ni-NAT agarose (0.4 mL, QIAGEN). The column was washed with
20 mL of Tris-HCl buffer with 0.1% Igepal CA-630. Then, a gradient
elution buffer (Tris-HCl) containing 5 to 300mMof imidazole (pH 8.0)
and 0.1% Igepal CA-630 was applied to elute the column over 15 column
volumes. Fractions containing His6-AftC (150 mM-200 mM of imi-
dazole) were identified by SDS-PAGE and Western blot. Protein
identity was confirmed using trypsin digestion andMascot search engine
(Proteomics and Metabolomics Facility located at Colorado State
University). The His6-Rv2673 was desalted on PD-10 column (GE
Healthcare) and stored in Tris-HCl with 10% (v/v) glycerol at80 C
until further use.
AftC Liposome Reconstitution. CHCl3/CH3OH-extracted
lipids (5 mg) fromM. tuberculosis H37Rv obtained from the Tuberculosis
Research Material Contract (NIH) at Colorado State University were
suspended in CHCl3 and then dried under a gentle stream of nitrogen.
One milliliter of the suspension buffer (1% Igepal CA-630 in 50 mM
buffer A) was added to the film. The solution was left at RT for 2 h and
was then sonicated. Purified recombinant AftC (200 μg) was added to
the lipiddetergent mixture. The mixture was allowed to stand for
30 min on ice. Activated and washed BioBeads (300 mg) were added,
and the mixture was stirred overnight at 4 C to allow gentle removal of
the detergent and incorporation of the AftC into the lipid bilayer. The
BioBeads were removed, 250 μL of the fresh batch was added, and the
suspension was stirred for 1 h at 4 C. The mixture was centrifuged for
15 min (10,000  g, 4 C) and separated into a pellet and a milky
supernatant containing AftC proteoliposome. The protein concentra-
tion of proteoliposome was determined by BCA method.
Arabinosyltransferase Assays Using AftC Proteoliposome
and DPA Analogues and Analysis by MALDI-TOF-MS. A
typical reaction mixture of 100 μL total volume contained 2 μM of
Rv2673 proteoliposome, 1 mM acceptor 15, and 2 mM Araf donor
(Z-FPA orZ-HPA) in buffer A. Reactions were incubated at RT for 2 h at
37 C and then terminated by adding 666 μL of 1:1 CHCl3/MeOH to
make a final CHCl3/MeOH/H2O of 10:10:3. The reaction mixture was
centrifuged at 14,000 rpm for 10 min. The supernatant was evaporated
to dryness in a SpeedVac. The dried samples were directly per-O-
methylated and then subjected to MALDI-TOF-MS in the positive
ionization mode according to the methods described previously.21 Since
the penta-arabinosyl acceptor and the hexa-arabinosyl enzymatic pro-
duct are expected to have very similar properties during MALDI-TOF-
MS and are present together in the sample and their ions collected in the
same laser acquisition, we hypothesized that the area of the M þ Naþ
ions peaks would be proportional to the abundance of the actual
oligosaccharides present. This hypothesis was tested using known ratios
of synthetic octyl hexa-arabinoside and synthetic octyl penta-arabinoside
(molar ratios of 1, 0.5, 0.25, and 0.125 were tested). Indeed a linear
relationship between the ratio of the two oligosaccharides and the ratio
of their respective MþNaþ ion peaks was found. A standard curve was
generated as presented in Supporting Information Figure S5. This
standard curve was then used to calculate the ratio of product to
substrate from the ratio of the M þ Naþ ion peaks in actual samples.
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